Moreover, supplementation with ketone ester formulations, which have previously shown benefits in patients with FAO disorders (i.e., MAD, CACT, CPT2 deficiencies) [[72], [73], [74]] and inborn errors of ketogenesis (i.e., mHL deficiency) [74], as well as a low-fat maternal diet during pregnancy and lactation, would be interesting avenues to explore in the treatment and prevention of fatty liver in our postnatal ketogenic deficient mice. Here, CPT2 is linked to fatty liver disease.